A PHASE II/III, DOUBLE-BLIND, TWO-GROUP INTERVENTIONAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORALLY ADMINISTERED PF-07321332/RITONAVIR COMPARED TO PLACEBO IN SYMPTOMATIC NON-HOSPITALIZED ADULT PATIENTS WITH COVID-19 WHO HAVE
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: PFIZER, SLU
- Phase: III
- Execution start: 03/08/2021
- End of execution: 30/03/2022
- PI: JUAN PASQUAU LIAÑO